EMA Authorised: Ninlaro (ixazomib citrate) — Takeda Pharma A/S

View source ↗

Summary

Ninlaro (ixazomib citrate) has been authorised in the EU for multiple myeloma by Takeda Pharma A/S.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• NINLARO (ixazomib)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Takeda Pharma A/S. Decision date: 21/05/2026. Orphan medicine